Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics Chief Commercial Officer Vasanthavada Madhav reported a new stock grant and a related share sale. On January 20, 2026, he received 76,621 shares of restricted common stock at $0.00, which will vest in three equal parts on January 20, 2027, January 20, 2028, and January 20, 2029. On January 22, 2026, he sold 12,610 shares of common stock at a weighted average price of $5.2861 per share to cover tax obligations from restricted stock vesting. After these transactions, he directly beneficially owned 318,619 shares of Abeona common stock.
Abeona Therapeutics’ Chief Commercial Officer, Madhav Vasanthavada, has reported his initial beneficial ownership in the company’s stock. He directly holds 254,608 shares of common stock, which include 176,384 shares of unvested restricted stock scheduled to vest on various dates between January 21, 2026 and January 21, 2028.
He also holds an employee stock option to purchase 2,400 shares of common stock at an exercise price of $4.00 per share, expiring on June 15, 2032. This option became exercisable as to 600 shares on June 15, 2023 and then in 36 equal monthly installments thereafter, providing a gradual vesting schedule over time.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano sold 18,666 shares of common stock on January 22, 2026 at a weighted average price of $5.3309 per share. The filing explains that this sale was made to cover tax obligations tied to the vesting of restricted stock awards, meaning it was related to compensation rather than an open-market liquidation of a large personal position.
After this tax-related sale, Vazzano beneficially owned 568,560 shares of Abeona common stock directly. The reported price reflects multiple trades in a range from $5.33 to $5.38 per share, aggregated into a single weighted average figure in the filing.
Abeona Therapeutics CEO Vishwas Seshadri, who also serves as a director, reported a sale of company common stock. On January 22, 2026, he sold 69,832 shares of Abeona Therapeutics common stock in an open market transaction coded as a sale. The shares were sold at a weighted average price of $5.3309 per share, through multiple trades at prices ranging from $5.33 to $5.38.
According to the filing, this sale was made to cover tax obligations associated with the vesting of restricted stock awards. After the transaction, Seshadri beneficially owned 1,460,408 shares of Abeona Therapeutics common stock directly.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley reported a sale of company stock. On January 22, 2026, he sold 13,578 shares of common stock at a weighted average price of $5.3309 per share. According to the filing, the sale was made to cover tax obligations associated with the vesting of restricted stock awards, meaning it was tied to equity compensation rather than an open-market discretionary sale of his full holdings. After this transaction, O'Malley beneficially owned 451,134 shares of Abeona common stock directly.
Abeona Therapeutics (ABEO) has a holder planning to sell 12,610 shares of common stock through broker Stifel Nicolaus & Company on or about 01/22/2026 on the Nasdaq market, with an aggregate market value of $66,658.00. The notice states that there were 54,191,361 shares of this class outstanding. The shares to be sold relate to restricted stock units that were acquired from the issuer on 01/21/2026 as equity compensation, in an amount of 25,048 shares. The person filing represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Abeona Therapeutics investor plans small stock sale under Rule 144. A notice was filed to potentially sell 18,666 shares of Abeona Therapeutics common stock through broker Stifel Nicolaus & Company on or after 01/22/2026 on the Nasdaq market. The aggregate market value of the proposed sale is listed as $99,507.00.
The shares relate to equity compensation. The filer acquired 48,169 shares of common stock on 01/21/2026 through restricted stock units granted by the issuer, with “equity compensation” described as the form of payment. The filing also notes that 51,191,361 shares of Abeona common stock were outstanding, providing context for the size of the planned sale.
ABEO has a planned insider sale under Rule 144. A holder has filed to sell 13,578 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $73,233.00. The shares relate to an award of 38,535 restricted stock units the holder acquired from the issuer on 01/21/2026 as equity compensation, with the planned sale date around 01/22/2026 on the Nasdaq exchange.
The filing notes that 54,191,361 shares of common stock were outstanding, providing context for the size of the planned sale relative to the company’s total share count.
Abeona Therapeutics (ABEO) insider Vishwas Seshadri has filed a notice of proposed stock sales under Rule 144. The filing covers 69,832 shares of common stock to be sold through Stifel Nicolaus & Company on the Nasdaq exchange, with an aggregate market value of
The securities to be sold were acquired on
Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.
The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.